Speciality: Dermatology
Description:
A warm welcome to all the medical professionals in this interesting session on Recent Updates in treatment of Urticaria
Recent advancements in the treatment of urticaria, particularly chronic spontaneous urticaria (CSU), have brought new hope for patients struggling with this condition. Traditionally managed with antihistamines, treatment approaches are evolving with the introduction of biologics like omalizumab, an anti-IgE monoclonal antibody. Omalizumab has shown significant efficacy in reducing hives and itchiness in patients who do not respond adequately to high doses of antihistamines, offering a targeted and effective alternative.
In addition to biologics, there is growing interest in the role of other immunomodulatory therapies in managing urticaria. Research into medications such as cyclosporine, which suppresses the immune system, has shown promise for patients with severe, refractory cases. These therapies provide additional options for individuals who have exhausted standard treatments, highlighting the importance of personalized medicine in addressing the diverse needs of urticaria patients.
Therefore, get an overall knowledge of recent updates in treatment of urticaria
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation